Literature DB >> 18240888

The challenge of compliance and persistence: focus on ulcerative colitis.

Sunanda V Kane1, Diana Brixner, David T Rubin, Maida J Sewitch.   

Abstract

BACKGROUND: Non-adherence to therapy is a widespread problem, with typical adherence rates for prescribed medications being approximately 50%. An estimated 20% to 50% of patients with ulcerative colitis (UC) do not take their medications as prescribed, resulting in higher disease-recurrence rates and potentially higher health care costs.
OBJECTIVE: To characterize the problem of non-adherence in UC, to review the many factors affecting compliance and persistence in this population, and to discuss practical strategies to improve adherence in these patients.
SUMMARY: Adherence to and persistence with medication are complex and multifactorial behaviors. Factors shown to affect adherence in UC patients include disease extent and duration, cost of medications, fear of adverse effects, individual psychosocial variables, and the patient-physician relationship. In contrast, recent data do not support an important role for treatment-related factors such as daily dose, regimen, and formulation in influencing adherence in this population, particularly with longer duration of use. Strategies to improve adherence should involve the patient, the provider, and the health care delivery system. For UC patients, knowledge and discussion of the rationale for supporting persistence, such as recent data regarding agents that have a potential chemoprotective benefit, may encourage persistence, even during periods of quiescence. The patient-physician relationship is critical in encouraging adherence, particularly with respect to education, open communication, and agreement regarding the value of the assigned treatment. Health care delivery systems can improve adherence by encouraging the participation of multidisciplinary teams, providing reporting and tracking systems, and eliminating financial barriers where possible.

Entities:  

Mesh:

Year:  2008        PMID: 18240888     DOI: 10.18553/jmcp.2008.14.s1-a.1a

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


  18 in total

1.  Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment.

Authors:  Paul Hodgkins; Paul Swinburn; Dory Solomon; Linnette Yen; Sarah Dewilde; Andrew Lloyd
Journal:  Patient       Date:  2012       Impact factor: 3.883

2.  Possible interactions between dietary fibres and 5-aminosalicylic acid [corrected].

Authors:  Camilla Henriksen; Steen Hansen; Inge Nordgaard-Lassen; Jens Rikardt Anderson; Pia Madsen
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

Review 3.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors:  Yongjun Wang; Claire E Parker; Tania Bhanji; Brian G Feagan; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-04-21

Review 4.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Authors:  Yongjun Wang; Claire E Parker; Brian G Feagan; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-05-09

5.  Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database.

Authors:  Sunanda V Kane; Michael Sumner; Dory Solomon; Matthew Jenkins
Journal:  Dig Dis Sci       Date:  2011-08-31       Impact factor: 3.199

6.  Self-reported treatment adherence in inflammatory bowel disease in Indian patients.

Authors:  Jay Bhatt; Samir Patil; Anand Joshi; Philip Abraham; Devendra Desai
Journal:  Indian J Gastroenterol       Date:  2009-11-24

7.  High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease.

Authors:  Edward L Barnes; Millie D Long; Michael D Kappelman; Christopher F Martin; Robert S Sandler
Journal:  Inflamm Bowel Dis       Date:  2019-06-18       Impact factor: 5.325

8.  Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis.

Authors:  Caroline Baehler; Beat Brüngger; Eva Blozik; Stephan R Vavricka; Alain M Schoepfer
Journal:  Inflamm Intest Dis       Date:  2019-08-07

9.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Authors:  Alistair Murray; Tran M Nguyen; Claire E Parker; Brian G Feagan; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2020-08-28

10.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors:  Alistair Murray; Tran M Nguyen; Claire E Parker; Brian G Feagan; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2020-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.